Trial · NCT02061384
RA-2 13-cis Retinoic Acid (Isotretinoin)
NCT02061384, Phase 2, Completed, University of Washington; results first posted 2021-07-30
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. RA-2 13-cis Retinoic Acid (Isotretinoin). Trials, record NCT02061384. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02061384
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- RA-2 13-cis Retinoic Acid (Isotretinoin)
- NCT number
- NCT02061384
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 20 participants, actual
- Lead sponsor
- University of Washington
- Conditions
- Male Infertility, Klinefelter's Syndrome, Y-chromosome Microdeletions
- Interventions
- 13-cis retinoic acid, Calcitriol
- First posted
- 2014-02-12
- Last updated
- 2021-08-02
- Results first posted
- 2021-07-30
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Millions of Sperm Per Ejaculate | Up to 20-weeks | Millions of sperm per ejaculate in men treated with 13-cis retinoic acid |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Millions of Sperm Per Ejaculate | Up to 20-weeks | First 10 men received isotretinoin alone, next 10 men received both isotretinoin and calcitriol | Millions of sperm per ejaculate | MEDIAN |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Millions of Sperm Per Ejaculate | 13-cis Retinoic Acid | 2.5 | Inter-Quartile Range 0.1 to 5.9 | Millions of sperm per ejaculate | |
| Millions of Sperm Per Ejaculate | Calcitriol 0.25 mcg | 3.8 | Inter-Quartile Range 2.1 to 13.0 | Millions of sperm per ejaculate |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | 13-cis Retinoic Acid + Oral Calcitriol | 10 | |
| Overall Study | STARTED | 13-cis Retinoic Acid | 10 | |
| Overall Study | COMPLETED | 13-cis Retinoic Acid + Oral Calcitriol | 10 | |
| Overall Study | COMPLETED | 13-cis Retinoic Acid | 10 | |
| Overall Study | NOT COMPLETED | 13-cis Retinoic Acid + Oral Calcitriol | 0 | |
| Overall Study | NOT COMPLETED | 13-cis Retinoic Acid | 0 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Upper respiratory infection | Respiratory, thoracic and mediastinal disorders | 13-cis Retinoic Acid + Oral Calcitriol | 1 | 10 | |
| other | Upper respiratory infection | Respiratory, thoracic and mediastinal disorders | 13-cis Retinoic Acid | 1 | 10 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | 13-cis Retinoic Acid + Oral Calcitriol | 0 | 10 |
| Total, all-cause mortality | 13-cis Retinoic Acid | 0 | 10 |
| Total, other adverse events | 13-cis Retinoic Acid + Oral Calcitriol | 1 | 10 |
| Total, other adverse events | 13-cis Retinoic Acid | 1 | 10 |
| Total, serious adverse events | 13-cis Retinoic Acid + Oral Calcitriol | 0 | 10 |
| Total, serious adverse events | 13-cis Retinoic Acid | 0 | 10 |
Source ClinicalTrials.gov
Papers23
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| 13-cis Retinoic Acid + Oral Calcitriol vs 13-cis Retinoic Acid: deaths from any cause | Trial comparisons |
| 13-cis Retinoic Acid + Oral Calcitriol vs 13-cis Retinoic Acid: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02061384
GET https://conductscience.org/api/trials/v1/NCT02061384/papers?page=2